Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,703 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
Shernan SK, Fitch JC, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF, Malloy KJ, Todaro TG, Filloon T, Boyce SW, Gangahar DM, Goldberg M, Saidman LJ, Mangano DT; Pexelizumab Study Investigators. Shernan SK, et al. Among authors: chen jc. Ann Thorac Surg. 2004 Mar;77(3):942-9; discussion 949-50. doi: 10.1016/j.athoracsur.2003.08.054. Ann Thorac Surg. 2004. PMID: 14992903 Clinical Trial.
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
Smith PK, Shernan SK, Chen JC, Carrier M, Verrier ED, Adams PX, Todaro TG, Muhlbaier LH, Levy JH; PRIMO-CABG II Investigators. Smith PK, et al. Among authors: chen jc. J Thorac Cardiovasc Surg. 2011 Jul;142(1):89-98. doi: 10.1016/j.jtcvs.2010.08.035. Epub 2010 Sep 28. J Thorac Cardiovasc Surg. 2011. PMID: 20880552 Free article. Clinical Trial.
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
Verrier ED, Shernan SK, Taylor KM, Van de Werf F, Newman MF, Chen JC, Carrier M, Haverich A, Malloy KJ, Adams PX, Todaro TG, Mojcik CF, Rollins SA, Levy JH; PRIMO-CABG Investigators. Verrier ED, et al. Among authors: chen jc. JAMA. 2004 May 19;291(19):2319-27. doi: 10.1001/jama.291.19.2319. JAMA. 2004. PMID: 15150203 Clinical Trial.
Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study.
Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, Jessel A, Kereiakes D, Knight J, Thulin L, Theroux P; GUARD During Ischemia Against Necrosis (GUARDIAN) Study Investigators. Boyce SW, et al. Among authors: chen jc. J Thorac Cardiovasc Surg. 2003 Aug;126(2):420-7. doi: 10.1016/s0022-5223(03)00209-5. J Thorac Cardiovasc Surg. 2003. PMID: 12928639 Free article. Clinical Trial.
2,703 results